Kit and method for screening prostate cancer

Abstract

The invention relates to the technical field of biology, provides a kit and a method for screening prostate cancer and aims at solving the risk assessment problem of the prostate cancer. The kit for screening the prostate cancer, provided by the invention, comprises an ERG primer and a probe thereof, an SPDF primer and a probe thereof, an MAX primer and a probe thereof, an IL32 primer and a probethereof as well as a PDGFA primer and a probe thereof; and an internal control is an SPK primer and a probe thereof. By adopting the kit, a specimen is collected by adopting a non-invasive means, real-time dynamic detection can be performed, and the detection accuracy is high.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a kit and method for screening prostate cancer. Background technique [0002] Existing prostate cancer screening methods include protein marker detection, DNA marker detection, RNA marker detection, miRNA-based biomarker detection and other methods. [0003] Detection of protein markers: PSA is tissue-specific and only exists in the cytoplasm of human prostate acinar and ductal epithelial cells, and is not expressed in other cells. However, it is not tumor-specific, and prostatitis, benign prostatic hyperplasia, and prostate cancer can all lead to elevated total PSA levels (free PSA plus composite PSA). While PSA is the most commonly used test for prostate cancer, benign prostatic hyperplasia and prostatitis can also produce positive PSA results. The normal value of serum prostate specific antigen (PSA) is generally <4ng / mL, and when prostate cancer occurs, PSA>10ng / mL, which...

AI Technical Summary

Problems solved by technology

[0007] Traditional protein markers, non-tumor-specific, have a significant increase in prostatitis and other diseases, and their increase will also lead to excessive diagnosis and treatment of prostate cancer; molecular markers: such as GSTP1 gene methylation, PCA3 gene excess Expression, etc., the specificity and sensitivity of PCA3 detection are not ideal, which are 33.6% and 90% respectively, and the methylation detection of GSTP1 is not particularly good in China, relying on the experimental skills of technical personnel, and cannot be widely promoted; The detection of miRNA markers can only be used to detect poorly differentiated sources, and patients with uncertain tumors can be detected by this method